Clinical trial
A Phase I/II Study of Chemoradiotherapy Using Albumin-Bound Paclitaxel and Cisplatin in Unresectable Esophageal Squamous Cell Carcinomas Based on Nutritional Risk Screening Score (NRS2002)
NCT04278287 is registered in ClinicalTrials.gov with Cancer Institute and Hospital, Chinese Academy of Medical Sciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II Study of Chemoradiotherapy Using Albumin-Bound Paclitaxel and Cisplatin in Unresectable Esophageal Squamous Cell Carcinomas Based on Nutritional Risk Screening Score (NRS2002)
- Lead sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- October 1, 2019
- Completion date
- December 31, 2026
- Enrollment
- 105 (estimated)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
albumin-bound paxlitaxel, chemoradiotherapy, esophageal cancer, unresectable malignant neoplasm